1. Hoffmann-la Roche Inc. (10 from 4,945 patents)

2. Chugai Seiyaku Kabushiki Kaisha (10 from 949 patents)

3. Basilea Pharmaceutica Ag (7 from 68 patents)

4. Roche Palo Alto LLC (4 from 322 patents)

5. Other (2 from 832,843 patents)

6. The University of Tokyo (1 from 1,285 patents)

7. Syntex (u.s.a.) Inc. (1 from 932 patents)

8. Basilea Pharmaceutica Ag, a Swiss Company (1 from 2 patents)

9. Hoshino, Tatsuo (0 patent)

1. 11298358 - Combination therapy using ascochlorin derivative

2. 10968186 - Ascochlorin derivative and use thereof as AMPK activator

3. 8648054 - 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication

4. 8609656 - Heteroarylphenylurea derivative

5. 8575391 - 5-substituted-2-phenylamino benzamides as MEK inhibitors

6. 8362236 - Macrocyclic compound

7. 8299252 - Pyrazolopyridine and pyrrolopyridine multikinase inhibitors

8. 8084645 - 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors

9. 8071567 - 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication

10. 8048897 - Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes

11. 8022205 - Pyrimidine derivatives as PI3K inhibitor and use thereof

12. 7915232 - 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication

13. 7745663 - 5-Substituted-2-phenylamino benzamides as MEK inhibitors

14. 7608601 - 4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication

15. 7459561 - N-substituted carbamoyloxyalkyl-azolium derivatives